cMET promotes metastasis and epithelial‐mesenchymal transition in colorectal carcinoma by repressing RKIP
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.30142
Abstract: Increasing evidence indicates that c‐mesenchymal‐epithelial transition factor (cMET) plays an important role in the malignant progression of colorectal cancer (CRC). However, the underlying mechanism is not fully understood. As a metastasis suppressor, raf kinase inhibitory… read more here.
Keywords: mesenchymal transition; rkip; epithelial mesenchymal; cmet ... See more keywords
Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-018-2634-4
Abstract: PurposeLung cancer is the leading cause of cancer-related death worldwide. Lung adenocarcinoma harboring EGFR-activating mutations will inevitably acquire resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs). EGFR T790M mutation and cMET amplification are common mechanisms.… read more here.
Keywords: lung adenocarcinoma; first generation; generation egfr; resistance first ... See more keywords
Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers of Medicine"
DOI: 10.1007/s11684-021-0869-y
Abstract: Cabozantinib, mainly targeting cMet and vascular endothelial growth factor receptor 2, is the second-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, the lower response rate and resistance limit its enduring clinical benefit. In… read more here.
Keywords: hepatocellular carcinoma; cmet inhibitor; rapamycin; cmet ... See more keywords
Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Annals of diagnostic pathology"
DOI: 10.1016/j.anndiagpath.2018.04.004
Abstract: PURPOSE To evaluate the incidence of cMET proto-oncogene aberration in a cohort of triple negative breast cancers using immunohistochemistry and fluorescence in situ hybridization (FISH) methods and correlated with patient outcome. PATIENTS AND METHODS One… read more here.
Keywords: triple negative; breast; cmet overexpression; cmet ... See more keywords
Abstract 4494: Multi-specific cMet x EGFR x VEGF antibody for difficult to treat cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4494
Abstract: Cancers such as TNBC, pancreatic, and gastric are difficult to treat due to diverse etiologies. Several subtypes of these cancers are driven by abnormal EGFR signaling, increased cMET activation, and VEGF linked angiogenesis which are… read more here.
Keywords: toxicology; vegf; cmet; treat ... See more keywords
Abstract 5000: MYTX-011: A novel cMET-targeting antibody drug conjugate (ADC) engineered to increase on-target uptake in and efficacy against cMET expressing tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5000
Abstract: MET alterations can act as an oncogenic driver in non-small cell lung cancer (NSCLC) and elevated cMET expression occurs in many cancers. Antibody drug conjugates targeting cMET (cMET-ADCs) have been developed as a strategy to… read more here.
Keywords: cmet; adc; mytx 011; efficacy ... See more keywords